Prof Van Cutsem meets with ecancertv at ESMO 2016 to discuss the different treatment profiles of left or right sided colon cancers, as determined through the CRYSTAL study.

He describes how, depending on the tumour locations in reference to the splenic fracture, left sided tumours  responded more to the cetuximab FOLFIRI being administered in the trial, and considers how sidedness as a substitute for biomarkers is only a starting point for prognosis. 

Dr Van Cutsem reflects on other presentations from the conference, how they will guide clinical development and may result in improvements of care.

He also spoke with ecancer about the outcomes of the LUME study of nintedanib for colon cancer here.